Matt Hoffman

Matt Hoffman, Managing Editor for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He hosts the NeurologyLive Mind Moments podcast, as well as the Medical World News show, Second Opinion. Follow him on Twitter @byMattHoffman or email him at


Moving Toward a More Personalized MS Treatment Journey

November 25, 2021

The field of MS is shifting focus to issues such as understanding and tracking disease progression, approaches to treatment initiation, and the roles of diet and exercise in pathogenesis and disease course.

The Cost of Alzheimer Disease: Aducanumab’s Price and the Implications for CMS, Patients

November 24, 2021

Aducanumab’s (Aduhelm; Biogen) $56,000 price point reflects the larger challenges of the United States’ insurance system and incites a cyclical series of events that have repercussions on cost of future therapies, state budgets, and legislative decisions.

Karl Doghramji, MD, on the Advances in Sleep Disorder Care in 2021

November 24, 2021

The medical director of the Jefferson Sleep Disorders Center at the Vickie and Jack Farber Institute for Neuroscience of Jefferson Health offered his insight into the current state of care for sleep and the progress made this year.

AAN Issues Statement on Ethical Considerations for Aducanumab Use in Alzheimer Disease

November 23, 2021

The American Academy of Neurology’s statement touched on the roles played by the principles of beneficence, nonmaleficence, justice, and patient autonomy as it relates to the clinical use of the therapy for this patient population.

Anna Kratz, PhD, on Managing MS Fatigue in a Multifaceted Way

November 16, 2021

Anna Kratz, PhD, associate professor of Physical Medicine & Rehabilitation, University of Michigan Medicine, spoke to the benefits of a multifaceted approach to managing fatigue for patients with multiple sclerosis.

Correlation Between Plasma Tau Reduction, Cognitive Function Linked to Aducanumab Treatment

November 11, 2021

The data, which suggest that a lessened decline in cognition and function was correlated with a reduction in plasma p-tau181 levels in those with Alzheimer disease treated with aducanumab (Aduhelm; Biogen), were presented at CTAD 2021.